Literature DB >> 13773933

Drug-induced extrapyramidal reactions. Treatment with diphenhydramine hydrochloride and dihydroxyphenylalanine.

P L MCGEER, J E BOULDING, W C GIBSON, R G FOULKES.   

Abstract

Entities:  

Keywords:  PARALYSIS AGITANS/therapy; TRANQUILIZING AGENTS/toxicology

Mesh:

Substances:

Year:  1961        PMID: 13773933     DOI: 10.1001/jama.1961.03040360001001

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  28 in total

1.  Extrapyramidal effects of neuroleptics.

Authors:  A D Korczyn; G J Goldberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-09       Impact factor: 10.154

2.  AN APPARENTLY IRREVERSIBLE SYNDROME OF ABNORMAL MOVEMENTS FOLLOWING PHENOTHIAZINE MEDICATION.

Authors:  R HUNTER; C J EARL; S THRONICROFT
Journal:  Proc R Soc Med       Date:  1964-08

3.  [THE EFFICACY OF L-DOPA IN PARKINSON PATIENTS WITH AND WITHOUT STEREOTACTIC BRAIN SURGERY].

Authors:  W UMBACH; D BAUMANN
Journal:  Arch Psychiatr Nervenkr       Date:  1964-06-01

4.  The pathogenesis of Parkinson's disease: a new hypothesis.

Authors:  A BARBEAU
Journal:  Can Med Assoc J       Date:  1962-10-13       Impact factor: 8.262

5.  Dopaminergic regulation of striatal cholinergic interneurons: an in vivo microdialysis study.

Authors:  G Damsma; P de Boer; B H Westerink; H C Fibiger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-11       Impact factor: 3.000

6.  Synaptic regulation of action potential timing in neostriatal cholinergic interneurons.

Authors:  B D Bennett; C J Wilson
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

7.  Modification of the tremorigenic activity of physostigmine.

Authors:  L M Ambrani; M H Van Woert
Journal:  Br J Pharmacol       Date:  1972-10       Impact factor: 8.739

8.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  The metabolism of orally administered L-Dopa in Parkinsonism.

Authors:  D B Calne; F Karoum; C R Ruthven; M Sandler
Journal:  Br J Pharmacol       Date:  1969-09       Impact factor: 8.739

10.  Levodopa therapy for Parkinsonism in the Shy-Drager syndrome.

Authors:  M J Aminoff; C S Wilcox; M M Woakes; M Kremer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-06       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.